Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients.
Circulating cell-free DNA (cfDNA)
Circulating soluble HER2 (sHER2)
HER2-positive breast cancer
Liquid biopsy
Trastuzumab emtansine (T-DM1)
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
29 Jun 2024
29 Jun 2024
Historique:
received:
12
02
2024
accepted:
20
06
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
epublish
Résumé
During targeted treatment, HER2-positive breast cancers invariably lose HER2 DNA amplification. In contrast, and interestingly, HER2 proteins may be either lost or gained. To longitudinally and systematically appreciate complex/discordant changes in HER2 DNA/protein stoichiometry, HER2 DNA copy numbers and soluble blood proteins (aHER2/sHER2) were tested in parallel, non-invasively (by liquid biopsy), and in two-dimensions, hence HER2-2D. aHER2 and sHER2 were assessed by digital PCR and ELISA before and after standard-of-care treatment of advanced HER2-positive breast cancer patients (n=37) with the antibody-drug conjugate (ADC) Trastuzumab-emtansine (T-DM1). As expected, aHER2 was invariably suppressed by T-DM1, but this loss was surprisingly mirrored by sHER2 gain, sometimes of considerable entity, in most (30/37; 81%) patients. This unorthodox split in HER2 oncogenic dosage was supported by reciprocal aHER2/sHER2 kinetics in two representative cases, and an immunohistochemistry-high status despite copy-number-neutrality in 4/5 available post-T-DM1 tumor re-biopsies from sHER2-gain patients. Moreover, sHER2 was preferentially released by dying breast cancer cell lines treated in vitro by T-DM1. Finally, sHER2 gain was associated with a longer PFS than sHER2 loss (mean PFS 282 vs 133 days, 95% CI [210-354] vs [56-209], log-rank test p=0.047), particularly when cases (n=11) developing circulating HER2-bypass alterations during T-DM1 treatment were excluded (mean PFS 349 vs 139 days, 95% CI [255-444] vs [45-232], log-rank test p=0.009). HER2 gain is adaptively selected in tumor tissues and recapitulated in blood by sHER2 gain. Possibly, an increased oncogenic dosage is beneficial to the tumor during anti-HER2 treatment with naked antibodies, but favorable to the host during treatment with a strongly cytotoxic ADC such as T-DM1. In the latter case, HER2-gain tumors may be kept transiently in check until alternative oncogenic drivers, revealed by liquid biopsy, bypass HER2. Whichever the interpretation, HER2-2D might help to tailor/prioritize anti-HER2 treatments, particularly ADCs active on aHER2-low/sHER2-low tumors. NCT05735392 retrospectively registered on January 31, 2023 https://www. gov/search?term=NCT05735392.
Sections du résumé
BACKGROUND
BACKGROUND
During targeted treatment, HER2-positive breast cancers invariably lose HER2 DNA amplification. In contrast, and interestingly, HER2 proteins may be either lost or gained. To longitudinally and systematically appreciate complex/discordant changes in HER2 DNA/protein stoichiometry, HER2 DNA copy numbers and soluble blood proteins (aHER2/sHER2) were tested in parallel, non-invasively (by liquid biopsy), and in two-dimensions, hence HER2-2D.
METHODS
METHODS
aHER2 and sHER2 were assessed by digital PCR and ELISA before and after standard-of-care treatment of advanced HER2-positive breast cancer patients (n=37) with the antibody-drug conjugate (ADC) Trastuzumab-emtansine (T-DM1).
RESULTS
RESULTS
As expected, aHER2 was invariably suppressed by T-DM1, but this loss was surprisingly mirrored by sHER2 gain, sometimes of considerable entity, in most (30/37; 81%) patients. This unorthodox split in HER2 oncogenic dosage was supported by reciprocal aHER2/sHER2 kinetics in two representative cases, and an immunohistochemistry-high status despite copy-number-neutrality in 4/5 available post-T-DM1 tumor re-biopsies from sHER2-gain patients. Moreover, sHER2 was preferentially released by dying breast cancer cell lines treated in vitro by T-DM1. Finally, sHER2 gain was associated with a longer PFS than sHER2 loss (mean PFS 282 vs 133 days, 95% CI [210-354] vs [56-209], log-rank test p=0.047), particularly when cases (n=11) developing circulating HER2-bypass alterations during T-DM1 treatment were excluded (mean PFS 349 vs 139 days, 95% CI [255-444] vs [45-232], log-rank test p=0.009).
CONCLUSIONS
CONCLUSIONS
HER2 gain is adaptively selected in tumor tissues and recapitulated in blood by sHER2 gain. Possibly, an increased oncogenic dosage is beneficial to the tumor during anti-HER2 treatment with naked antibodies, but favorable to the host during treatment with a strongly cytotoxic ADC such as T-DM1. In the latter case, HER2-gain tumors may be kept transiently in check until alternative oncogenic drivers, revealed by liquid biopsy, bypass HER2. Whichever the interpretation, HER2-2D might help to tailor/prioritize anti-HER2 treatments, particularly ADCs active on aHER2-low/sHER2-low tumors.
TRIAL REGISTRATION
BACKGROUND
NCT05735392 retrospectively registered on January 31, 2023 https://www.
CLINICALTRIALS
RESULTS
gov/search?term=NCT05735392.
Identifiants
pubmed: 38951853
doi: 10.1186/s13046-024-03105-9
pii: 10.1186/s13046-024-03105-9
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
Ado-Trastuzumab Emtansine
SE2KH7T06F
Trastuzumab
P188ANX8CK
Biomarkers, Tumor
0
Banques de données
ClinicalTrials.gov
['NCT05735392']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
182Subventions
Organisme : Lazio Innova
ID : A0375-2020-36630
Informations de copyright
© 2024. The Author(s).
Références
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364–82.
doi: 10.5858/arpa.2018-0902-SA
pubmed: 29846104
Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15(23):7381–8.
doi: 10.1158/1078-0432.CCR-09-1735
pubmed: 19920100
pmcid: 2788123
Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13(4):e178–85.
doi: 10.1016/S1470-2045(11)70335-7
pubmed: 22469128
Li G, Guo J, Shen BQ, Yadav DB, Sliwkowski MX, Crocker LM, et al. Mechanisms of acquired resistance to Trastuzumab Emtansine in breast cancer cells. Mol Cancer Ther. 2018;17(7):1441–53.
doi: 10.1158/1535-7163.MCT-17-0296
pubmed: 29695635
Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res. 2013;19(12):3276–84.
doi: 10.1158/1078-0432.CCR-12-3768
pubmed: 23637122
pmcid: 6485473
Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangpratheep C, et al. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011;104(8):1342–8.
doi: 10.1038/bjc.2011.89
pubmed: 21427727
pmcid: 3078598
Garcia-Murillas I, Lambros M, Turner NC. Determination of HER2 amplification status on tumour DNA by digital PCR. PLoS One. 2013;8(12):e83409.
doi: 10.1371/journal.pone.0083409
pubmed: 24386193
pmcid: 3873285
Ruifeng ZPY LZ, Shuangye S, Zhaoliang L, Yan W. Using digital PCR to detect HER2 amplifcation in breast and gastric cancer patients. Front Lab Med. 2018;2:102–8.
Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, et al. Clinical relevance of serum HER2 and circulating tumor cell detection in metastatic breast cancer patients. Anticancer Res. 2017;37(6):3117–28.
pubmed: 28551653
De Gregorio A, Friedl TWP, Huober J, Scholz C, De Gregorio N, Rack B, et al. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) phenotype between primary tumor and circulating tumor cells in women with HER2-negative metastatic breast cancer. JCO Precis Oncol. 2017;1:1–12.
doi: 10.1200/PO.17.00023
pubmed: 35172510
Deutsch TM, Riethdorf S, Fremd C, Feisst M, Nees J, Fischer C, et al. HER2-targeted therapy influences CTC status in metastatic breast cancer. Breast Cancer Res Treat. 2020;182(1):127–36.
doi: 10.1007/s10549-020-05687-2
pubmed: 32436146
pmcid: 7274999
Carney WP, Bernhardt D, Jasani B. Circulating HER2 extracellular domain: a specific and quantitative biomarker of prognostic value in all breast cancer patients? Biomark Cancer. 2013;5:31–9.
doi: 10.4137/BIC.S12389
pubmed: 24179396
pmcid: 3791951
Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle DA, Rothgiesser K, et al. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99. BMC Cancer. 2020;20(1):114.
doi: 10.1186/s12885-020-6594-0
pubmed: 32046665
pmcid: 7014942
Perrier A, Boelle PY, Chretien Y, Gligorov J, Lotz JP, Brault D, et al. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. PLoS One. 2020;15(1):e0227356.
doi: 10.1371/journal.pone.0227356
pubmed: 31910438
pmcid: 6946590
Wu Y, Li L, Zhang D, Ma F. Prognostic value of the serum HER2 extracellular domain level in breast cancer: a systematic review and meta-analysis. Cancers (Basel). 2022;14(19):4551. https://doi.org/10.3390/cancers14194551 .
Allegretti M, Fabi A, Giordani E, Ercolani C, Romania P, Nistico C, et al. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. Mol Cancer. 2021;20(1):151.
doi: 10.1186/s12943-021-01438-z
pubmed: 34839818
pmcid: 8628389
Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57(16):6949–64.
doi: 10.1021/jm500766w
pubmed: 24967516
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–90.
doi: 10.1158/0008-5472.CAN-08-1776
pubmed: 19010901
Allegretti M, Cottone G, Carboni F, Cotroneo E, Casini B, Giordani E, et al. Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. J Exp Clin Cancer Res. 2020;39(1):69.
doi: 10.1186/s13046-020-01569-z
pubmed: 32312295
pmcid: 7168847
Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990;45(3):457–61.
doi: 10.1002/ijc.2910450314
pubmed: 1968437
Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer. 1999;79(5–6):707–17.
doi: 10.1038/sj.bjc.6690114
pubmed: 10070858
pmcid: 2362677
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;382:610–21.
Nadal-Serrano M, Morancho B, Escriva-de-Romani S, Morales CB, Luque A, Escorihuela M, et al. The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers (Basel). 2020;12(3):670. https://doi.org/10.3390/cancers12030670 .